JPH0517332A - Skin medicine for external use - Google Patents
Skin medicine for external useInfo
- Publication number
- JPH0517332A JPH0517332A JP19598391A JP19598391A JPH0517332A JP H0517332 A JPH0517332 A JP H0517332A JP 19598391 A JP19598391 A JP 19598391A JP 19598391 A JP19598391 A JP 19598391A JP H0517332 A JPH0517332 A JP H0517332A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- saikosaponin
- effect
- saccharide
- effects
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title abstract description 5
- WRYJYFCCMSVEPQ-MNIDVGFKSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,4r,4ar,6ar,6bs,8s,8as,14ar,14bs)-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,14a-dodecahydropicen-3-yl]oxy]-3,5-dihydroxy-6-methyloxan-4-yl]oxy-6-(hydroxymethyl)oxane Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@H](O)[C@@]6(CO)CCC(C)(C)CC6=C5C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WRYJYFCCMSVEPQ-MNIDVGFKSA-N 0.000 claims abstract description 24
- WRYJYFCCMSVEPQ-ORAXXRKOSA-N Saikosaponin b2 Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@@H](O)[C@@]6(CO)CCC(C)(C)CC6=C5C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WRYJYFCCMSVEPQ-ORAXXRKOSA-N 0.000 claims abstract description 14
- 235000000346 sugar Nutrition 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 18
- 210000003491 skin Anatomy 0.000 abstract description 41
- 230000000694 effects Effects 0.000 abstract description 33
- 230000001976 improved effect Effects 0.000 abstract description 12
- 230000002265 prevention Effects 0.000 abstract description 8
- 210000004927 skin cell Anatomy 0.000 abstract description 7
- 230000004663 cell proliferation Effects 0.000 abstract description 6
- 229930192014 saikosaponin Natural products 0.000 abstract description 6
- -1 D-glyceraladehyde Chemical class 0.000 abstract description 5
- KYWSCMDFVARMPN-LCSVLAELSA-N Saikosaponin D Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-LCSVLAELSA-N 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 238000007788 roughening Methods 0.000 abstract description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract description 3
- 229930006000 Sucrose Natural products 0.000 abstract description 3
- 150000004676 glycans Chemical class 0.000 abstract description 3
- 238000002156 mixing Methods 0.000 abstract description 3
- 150000002772 monosaccharides Chemical class 0.000 abstract description 3
- 229920001282 polysaccharide Polymers 0.000 abstract description 3
- 239000005017 polysaccharide Substances 0.000 abstract description 3
- 239000005720 sucrose Substances 0.000 abstract description 3
- 206010052428 Wound Diseases 0.000 abstract description 2
- 208000027418 Wounds and injury Diseases 0.000 abstract description 2
- 239000001913 cellulose Substances 0.000 abstract description 2
- 229920002678 cellulose Polymers 0.000 abstract description 2
- GNVUHIXVRODVRA-UHFFFAOYSA-N saikosaponin-b2 Natural products CC1OC(OC2CCC3(C)C(CCC4(C)C3C=CC5=C6CC(C)(C)CCC6(CO)C(O)CC45C)C2(C)CO)C(O)C(O)C1OC7OC(CO)C(O)C(O)C7O GNVUHIXVRODVRA-UHFFFAOYSA-N 0.000 abstract 6
- 150000001720 carbohydrates Chemical class 0.000 abstract 4
- WRYJYFCCMSVEPQ-IPNFWLSTSA-N saikosaponin b1 Natural products C[C@H]1O[C@@H](O[C@H]2CC[C@@]3(C)[C@@H](CC[C@]4(C)[C@@H]3C=CC5=C6CC(C)(C)CC[C@]6(CO)[C@@H](O)C[C@]45C)[C@]2(C)CO)[C@H](O)[C@@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H]1O WRYJYFCCMSVEPQ-IPNFWLSTSA-N 0.000 abstract 3
- 239000002932 luster Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 239000012071 phase Substances 0.000 description 14
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 206010013786 Dry skin Diseases 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000029663 wound healing Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 3
- LNRUEZIDUKQGRH-UHFFFAOYSA-N Umbelliferose Natural products OC1C(O)C(CO)OC1(CO)OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(O)C(O)C(CO)O1 LNRUEZIDUKQGRH-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000007665 sagging Methods 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- LNRUEZIDUKQGRH-YZUCMPLFSA-N umbelliferose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 LNRUEZIDUKQGRH-YZUCMPLFSA-N 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- AEMOLEFTQBMNLQ-YBSDWZGDSA-N d-mannuronic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-YBSDWZGDSA-N 0.000 description 2
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Polymers OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 2
- MVLVMROFTAUDAG-UHFFFAOYSA-N ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC MVLVMROFTAUDAG-UHFFFAOYSA-N 0.000 description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000001651 pyrus cydonia seed extract Substances 0.000 description 2
- QLPRYZXNWYTFCI-UHFFFAOYSA-N saikosaponin D Natural products CC1OC(OC2CCC3(C)C(CCC4(C)C3C=CC56OCC7(CCC(C)(C)CC57)C(O)CC46C)C2(C)CO)C(O)C(O)C1OC8OC(CO)C(O)C(O)C8O QLPRYZXNWYTFCI-UHFFFAOYSA-N 0.000 description 2
- PQPVAGWUNWFCJE-UHFFFAOYSA-N saikosaponin a Natural products CC1OC(OC2CCC3(C)C(C2)C(C)(CO)CC4(C)C3C=CC56OCC7(CCC(C)(C)CC57)C(O)CC46C)C(O)C(OC8OC(CO)C(O)C(O)C8O)C1O PQPVAGWUNWFCJE-UHFFFAOYSA-N 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- VRUOTYGNKCHBJA-GRKSLAKBSA-N (2R,4R)-3-[(2R,3R,4R,5S)-5-[(1R)-1,2-dihydroxyethyl]-3,4-dihydroxyoxolan-2-yl]oxypentane-1,2,4,5-tetrol Chemical compound OC[C@@H](O)C(O[C@@H]1O[C@@H]([C@H](O)CO)[C@H](O)[C@H]1O)[C@H](O)CO VRUOTYGNKCHBJA-GRKSLAKBSA-N 0.000 description 1
- BNOGJEJAYILSFT-XNSRJBNMSA-N 1(F)-alpha-D-galactosylraffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1)O)CO[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 BNOGJEJAYILSFT-XNSRJBNMSA-N 0.000 description 1
- MSFSPUZXLOGKHJ-PGYHGBPZSA-N 2-amino-3-O-[(R)-1-carboxyethyl]-2-deoxy-D-glucopyranose Chemical compound OC(=O)[C@@H](C)O[C@@H]1[C@@H](N)C(O)O[C@H](CO)[C@H]1O MSFSPUZXLOGKHJ-PGYHGBPZSA-N 0.000 description 1
- JVXJFNLEXLGQIO-UHFFFAOYSA-N 2-hexyldecyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CCCCCC)CCCCCCCC JVXJFNLEXLGQIO-UHFFFAOYSA-N 0.000 description 1
- MSPJNHHBNOLHOC-UHFFFAOYSA-N 3,3-dimethylcyclopropane-1,2-dicarboxylic acid Chemical compound CC1(C)C(C(O)=O)C1C(O)=O MSPJNHHBNOLHOC-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 241000694440 Colpidium aqueous Species 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-DTEWXJGMSA-N D-Galacturonic acid Natural products O[C@@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-DTEWXJGMSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 description 1
- UQPHVQVXLPRNCX-GSVOUGTGSA-N D-erythrulose Chemical compound OC[C@@H](O)C(=O)CO UQPHVQVXLPRNCX-GSVOUGTGSA-N 0.000 description 1
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- BJHIKXHVCXFQLS-PUFIMZNGSA-N D-psicose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C(=O)CO BJHIKXHVCXFQLS-PUFIMZNGSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 description 1
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 1
- YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-OBAJZVCXSA-N Gentianose Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@H](O)[C@@H](CO)O2)O1)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-OBAJZVCXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- WQZGKKKJIJFFOK-DHVFOXMCSA-N L-galactose Chemical compound OC[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-DHVFOXMCSA-N 0.000 description 1
- IAJILQKETJEXLJ-SQOUGZDYSA-N L-guluronic acid Chemical compound O=C[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O IAJILQKETJEXLJ-SQOUGZDYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-JFNONXLTSA-N L-mannopyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-WVZVXSGGSA-N L-xylulose Chemical compound OC[C@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-WVZVXSGGSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- OSEGOMJCJRKRPD-UHFFFAOYSA-N Lychnose Natural products OCC1OC(O)C(OCC2(OC3OC(COC4OC(CO)C(O)C(O)C4O)C(O)C(O)C3O)OC(CO)C(O)C2O)C(O)C1O OSEGOMJCJRKRPD-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- NIBVDXPSJBYJFT-VBBCUDLLSA-N Planteose Natural products O(C[C@@H]1[C@H](O)[C@@H](O)[C@@](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)(CO)O1)[C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1 NIBVDXPSJBYJFT-VBBCUDLLSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- KYWSCMDFVARMPN-MSSMMRRTSA-N Saikosaponin A Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-MSSMMRRTSA-N 0.000 description 1
- VJEMOEYSQDKAQF-MJKDWHOWSA-N Saikosaponin C Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2C([C@H]3[C@](C4[C@@]([C@@]5(C[C@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)C)O[C@@H]1CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 VJEMOEYSQDKAQF-MJKDWHOWSA-N 0.000 description 1
- VSVPCEFIECVNTB-UHFFFAOYSA-N Saikosaponin c Natural products CC1OC(OC2C(O)C(O)C(OC3CCC4(C)C(C3)C(C)(C)CC5(C)C4C=CC67OCC8(CCC(C)(C)CC68)C(O)CC57C)OC2COC9OC(CO)C(O)C(O)C9O)C(O)C(O)C1O VSVPCEFIECVNTB-UHFFFAOYSA-N 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- YUSNDFRUEQZBJG-UHFFFAOYSA-N Umbilicin Natural products OCC(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C1O YUSNDFRUEQZBJG-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N aldehydo-D-galactose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- GZCGUPFRVQAUEE-KAZBKCHUSA-N aldehydo-D-talose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-KAZBKCHUSA-N 0.000 description 1
- 150000001304 aldoheptoses Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- ZDKCXSMMRXSSDE-UHFFFAOYSA-N chikusakoside II Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(OC2C(C3C(C4C(C5(CC(O)C67COC5(C6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)OC1COC1C(O)C(O)C(O)C(CO)O1 ZDKCXSMMRXSSDE-UHFFFAOYSA-N 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- BXKDSDJJOVIHMX-UHFFFAOYSA-N edrophonium chloride Chemical compound [Cl-].CC[N+](C)(C)C1=CC=CC(O)=C1 BXKDSDJJOVIHMX-UHFFFAOYSA-N 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- MUPFEKGTMRGPLJ-WSCXOGSTSA-N gentianose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-WSCXOGSTSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- AEMOLEFTQBMNLQ-CLQWQSTFSA-N l-iduronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O AEMOLEFTQBMNLQ-CLQWQSTFSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- NIBVDXPSJBYJFT-ZQSKZDJDSA-N planteose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 NIBVDXPSJBYJFT-ZQSKZDJDSA-N 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- VJEMOEYSQDKAQF-UHFFFAOYSA-N saikogenin E 3-O-beta-D-glucopyranosyl-(1?6)-[alpha-L-rhamnopyranosyl-(1?4)]-beta-D-glucopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(OC2C(C3C(C4C(C5(CC(O)C67COC5(C6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)C)OC1COC1C(O)C(O)C(O)C(CO)O1 VJEMOEYSQDKAQF-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- KMEHEQFDWWYZIO-UHFFFAOYSA-N triacontyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC KMEHEQFDWWYZIO-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、皮膚外用剤に係わり、
更に詳しくは高い皮膚細胞増殖効果を有する皮膚外用剤
に関する。本皮膚外用剤は、例えば、化粧水、クリー
ム、乳液、パック、頭皮用化粧料等の化粧品や、例え
ば、傷治療、消炎用軟膏等の医薬品に好適に適用され
る。The present invention relates to a skin external preparation,
More specifically, it relates to a skin external preparation having a high skin cell growth effect. The external preparation for skin is preferably applied to cosmetics such as lotions, creams, emulsions, packs, cosmetics for scalp, and pharmaceuticals such as ointment for treating wounds and anti-inflammatory.
【0002】[0002]
【従来の技術】柴胡等の植物から抽出されるサイコサポ
ニンは、皮膚の創傷治癒、肌あれ防止及び改善、皮膚の
たるみやつや消失を防ぐ老化防止等の効果があり、医薬
品、化粧品等に配合されている。2. Description of the Related Art Psychosaponin extracted from plants such as Saiko has effects such as wound healing on skin, prevention and improvement of skin roughness, and aging prevention to prevent sagging and loss of skin. It is compounded.
【0003】また、抽出されたサイコサポニンを、サイ
コサポニンa、サイコサポニンb1、サイコサポニン
b2、サイコサポニンc、サイコサポニンdに分離し、
各成分を単独で用いることにより、上記効果を高めた技
術も提案されている(特開昭61−7216号公報)。Further, the extracted saikosaponin is separated into saikosaponin a, saikosaponin b 1 , saikosaponin b 2 , saikosaponin c, and saikosaponin d,
A technique in which the above effects are enhanced by using each component alone has also been proposed (Japanese Patent Laid-Open No. 61-7216).
【0004】しかるに、これらよりもより一層上記効果
を高めた皮膚外用剤が望まれている。[0004] However, there is a demand for an external preparation for the skin which further enhances the above effects.
【0005】[0005]
【発明が解決しようとする課題】本発明は、皮膚の創傷
治癒、肌あれ防止及び改善、皮膚のたるみやつや消失を
防ぐ老化防止等の効果が従来よりもより一層改善された
皮膚外用剤を提供することを目的とする。DISCLOSURE OF THE INVENTION The present invention provides a skin preparation for external use, which has improved effects such as wound healing on the skin, prevention and improvement of skin roughness, and aging prevention to prevent sagging and loss of skin. The purpose is to provide.
【0006】[0006]
【課題を解決するための手段】本発明の第1の要旨はサ
イコサポニンb1及びサイコサポニンb2の少なくとも1
種と糖とを含有することを特徴とする皮膚外用剤に存在
する。The first gist of the present invention is to provide at least one of saikosaponin b 1 and saikosaponin b 2 .
It exists in an external preparation for skin characterized by containing seeds and sugar.
【0007】第2の要旨は、第1の要旨において、サイ
コサポニンb1及びサイコサポニンb2の少なくとも1種
を0.0001〜20重量%含むことを特徴とする皮膚
外用剤に存在する。A second aspect resides in the external preparation for skin according to the first aspect, which comprises 0.0001 to 20% by weight of at least one of saikosaponin b 1 and saikosaponin b 2 .
【0008】第3の要旨は、第1または2の要旨におい
て、前記糖を0.01〜20重量%含むことを特徴と皮
膚外用剤に存在する。A third gist resides in the external preparation for skin, which is characterized in that the sugar is contained in an amount of 0.01 to 20% by weight in the first or second gist.
【0009】以下に本発明の構成をを詳細に説明する。The structure of the present invention will be described in detail below.
【0010】本発明の皮膚外用剤においては、サイコサ
ポニンb1とサイコサポニンb2の少なくともどちらかが
配合される。配合量は、皮膚外用剤全量中0.0001
〜20重量%が好ましく、0.001〜10重量%がよ
り好ましい。0.001重量%以上で肌あれ改善効果は
一層向上する。また、10%重量以下では、べたつき感
がなくなり、刺激性がなくなる等の効果が生じる。In the external preparation for skin of the present invention, at least one of saikosaponin b 1 and saikosaponin b 2 is blended. The compounding amount is 0.0001 in the total amount of the external preparation for skin.
-20% by weight is preferable, and 0.001-10% by weight is more preferable. If it is 0.001% by weight or more, the skin roughening improving effect is further enhanced. On the other hand, if it is 10% by weight or less, the sticky feeling disappears and the stimulative effect disappears.
【0011】本発明の糖としては、例えば、単糖、オリ
ゴ糖あるいは多糖が用いられる。As the sugar of the present invention, for example, monosaccharide, oligosaccharide or polysaccharide is used.
【0012】単糖としては、例えば、D−グリセルアル
デヒド、ジヒドロキシアセトン等の三炭糖,D−エリト
ロース、D−エリトルロース、D−トレオース塔の四炭
糖、L−アラビノース、D−キシロース、L−リキソー
ス、D−アラビノース、D−リボース、D−リブロー
ス、D−キシルロース、L−キシルロース等の五炭糖、
D−グルコース、D−タロース、D−プシコース、D−
ガラクトース、D−フルクトース、L−ガラクトース、
L−ソルボース、D−マンノース、D−タガトース等の
六炭糖、アルドヘプトース、ヘプツロース等の七炭糖、
オクツロース等の八炭糖、2−デオキシ−D−デボー
ス、6−デオキシ−L−ガラクトース、6−デオキシ−
L−マンノース等のデオキシ糖、D−グルコサミン、D
−ガラクトサミン、シアル酸、アミノウロン酸、ムラミ
ン酸等のアミノ酸,D−グルクロン酸、D−マンヌロン
酸、L−グルロン酸、D−ガラクツロン酸、L−イズロ
ン酸等のウロン酸等があげられる。The monosaccharides include, for example, three-carbon sugars such as D-glyceraldehyde and dihydroxyacetone, D-erythrose, D-erythrulose, four-carbon sugars of a D-threose tower, L-arabinose, D-xylose and L. Pentoses such as lyxose, D-arabinose, D-ribose, D-ribulose, D-xylulose and L-xylulose,
D-glucose, D-talose, D-psicose, D-
Galactose, D-fructose, L-galactose,
L-sorbose, D-mannose, D-tagatose and other hexoses, aldoheptose, heptulose and other heptasaccharides,
Octoculose and other octose sugars, 2-deoxy-D-debose, 6-deoxy-L-galactose, 6-deoxy-
Deoxy sugars such as L-mannose, D-glucosamine, D
-Amino acids such as galactosamine, sialic acid, aminouronic acid, and muramic acid; uronic acids such as D-glucuronic acid, D-mannuronic acid, L-guluronic acid, D-galacturonic acid, and L-iduronic acid.
【0013】オリゴ糖としては、例えば、しょ糖、ゲン
チアノース、ウンベリフェロース、ラクトース、プラン
テオース、イソリクノース類、α,α−トレハロース、
ラフィノース、リクノース類、ウンビリシン、スタキオ
ースベルバスコース類があげられる。Examples of oligosaccharides include sucrose, gentianose, umbelliferose, lactose, planteose, isoliknoses, α, α-trehalose,
Raffinose, lychnose, umbilicin, and stachyose bell bass course.
【0014】多糖としては、例えば、セルロース、クイ
ンスシード、コンドロイチン硫酸、デンプン、ガラクタ
ン、デルマタン硫酸、グリコーゲン、アラビアガム、ヘ
パラン硫酸、ヒアルロン酸、トラガントガム、ケラタン
硫酸、コンドロイチン、キサンタンガム、ムコイチン硫
酸、グアガム、デキストラン、ケラト硫酸、ローカスト
ビンガム、サクシノグルカン、カロニン酸及びこれらの
塩があげられる。Examples of the polysaccharides include cellulose, quince seed, chondroitin sulfate, starch, galactan, dermatan sulfate, glycogen, gum arabic, heparan sulfate, hyaluronic acid, tragacanth gum, keratan sulfate, chondroitin, xanthan gum, mucoitin sulfate, guar gum and dextran. , Keratosulfate, locust bingham, succinoglucan, caronic acid and salts thereof.
【0015】本発明において、上記の糖の少なくとも1
種が配合される。これらの配合量は、皮膚外用剤全量中
0.01〜20重量%が好ましく、0.5〜15重量%
がより好ましい。0.5%以上で皮膚細胞増殖効果は一
層向上し、また15重量%以下で使用感がより一層向上
する。In the present invention, at least one of the above sugars
Seeds are blended. The blending amount of these is preferably 0.01 to 20% by weight, and 0.5 to 15% by weight in the total amount of the skin external preparation.
Is more preferable. When it is 0.5% or more, the skin cell proliferation effect is further improved, and when it is 15% by weight or less, the feeling of use is further improved.
【0016】以上述べたように、糖には、サイコサポニ
ンb1あるいはサイコサポニンb2の皮膚細胞増殖効果を
相乗的に促進する作用がある。すなわち、両者を共に配
合することにより、サイコサポニンの皮膚細胞増殖効
果、即ち肌あれ改善効果等は著しく向上する。As described above, sugar has an action of synergistically promoting the skin cell proliferation effect of saikosaponin b 1 or saikosaponin b 2 . That is, when both are blended together, the skin cell proliferation effect of Psychosaponin, that is, the effect of improving skin roughness, etc., is significantly improved.
【0017】本発明の皮膚外用剤は、上記の必須成分に
加えて、本発明の効果を損なわない範囲で、化粧品、医
薬品等に用いられる成分、例えば、水性成分、粉末成
分、油分、界面活性剤、保湿剤、増粘剤、防腐剤、酸化
防止剤、香料、色剤及び薬剤等を配合することができ
る。The external preparation for skin of the present invention contains, in addition to the above-mentioned essential components, components used in cosmetics, pharmaceuticals, etc., such as an aqueous component, a powder component, an oil component, and a surfactant, as long as the effects of the present invention are not impaired. Agents, moisturizers, thickeners, preservatives, antioxidants, fragrances, coloring agents, agents and the like can be added.
【0018】また、皮膚外用剤の剤型は任意であり、例
えば、化粧水等の可溶化系、乳液、クリーム等の乳化
系、軟膏、分散液等の剤型をとることができる。Further, the dosage form of the external preparation for skin is arbitrary, and for example, a solubilization system such as lotion, an emulsion system such as emulsion or cream, an ointment, a dispersion liquid and the like can be adopted.
【0019】[0019]
【実施例】次に実施例をあげて本発明を詳細に説明する
が、本発明の技術範囲がこれら実施例に限定されるもの
でないことはいうまでもない。EXAMPLES Next, the present invention will be described in detail with reference to examples, but it goes without saying that the technical scope of the present invention is not limited to these examples.
【0020】まず、サイコサポニンb1及びb2の皮膚の
創傷治癒、肌あれ防止及び改善、皮膚のたるみやつや消
失を防ぐ老化防止等の効果及び使用感が糖を配合するこ
とにより、相乗的に改善されることを示すために、皮膚
細胞増殖促進効果、創傷治癒効果及び刺激性(溶血作
用)抑制効果について以下の試験を行った。First, the effects of saikosaponins b 1 and b 2 on healing skin wounds, preventing and improving skin roughness, preventing aging to prevent sagging and loss of skin, and the feeling of use are synergistic by incorporating sugar. In order to show that the effect is improved, the following tests were carried out for skin cell proliferation promoting effect, wound healing effect and stimulating (hemolytic effect) suppressing effect.
【0021】(皮膚細胞増殖促進作用)人皮膚組織を細
片し、細胞培養用シャーレの底面に付着させてDulbecc
o's MEM培養液(10%牛胎児血清含有)中で2週間培
養すると、シャーレの底面がほぼ全面に線維芽細胞で満
たされる。この線維芽細胞を0.1%トリプシン溶液で
処理して単一細胞とし、1000個細胞/mlの培養液
を作製した。この溶液をシャーレ当り1ml採取し、こ
れにDulbecco's MEM培養液と種々の濃度のサイコサポ
ニンb1を加え、または更に糖を加えて、CO2−インキ
ュベーター中で2週間培養した。その後、細胞固定して
染色した後、細胞のコロニー数を計測した。 結果を図
1に示す。図1の実線は、サイコサポニンb1だけを培
養液に加えたときの結果であり、また、破線(実施例)
は、更に糖として、L−アラビノースを100ppm添
加した場合の結果である。図の細胞増殖率は、サイコサ
ポニンb1を添加しない場合の細胞数を基準とし、それ
に対する比で表した。(Skin cell proliferation promoting action) Human skin tissue is cut into small pieces and attached to the bottom surface of a cell culture dish to give Dulbecc.
After culturing in o's MEM culture solution (containing 10% fetal bovine serum) for 2 weeks, the bottom surface of the petri dish is almost entirely filled with fibroblasts. The fibroblasts were treated with a 0.1% trypsin solution to give single cells, and a culture medium containing 1000 cells / ml was prepared. This solution was sampled in an amount of 1 ml per dish, to which Dulbecco's MEM culture medium and various concentrations of saikosaponin b 1 were added, or sugar was further added, and the mixture was cultured for 2 weeks in a CO 2 -incubator. Then, the cells were fixed and stained, and the number of cell colonies was counted. The results are shown in Fig. 1. The solid line in FIG. 1 is the result when only saikosaponin b 1 was added to the culture solution, and the broken line (Example)
Is the result when 100 ppm of L-arabinose was further added as a sugar. The cell growth rate in the figure was expressed as a ratio based on the number of cells without the addition of saikosaponin b 1 .
【0022】図から明らかなように、糖を添加すること
により、細胞増殖率は大幅に向上した。サイコサポニン
b2についても、同様の結果が得られた。As is clear from the figure, the cell growth rate was significantly improved by adding sugar. Similar results were obtained with saikosaponin b 2 .
【0023】(創傷治癒効果)生後6週間のウイスター
系ラット5匹を1群とし、毛刈りの後試験に供した。ラ
ットはネンプタールにより麻酔後、正中線に沿って背部
皮膚を約2cm切開した、直ちに切開部をミツヘル縫合
し、サイコサポニンb1200mgを生理食塩水0.1
mlに溶解したもの、あるいはサイコサポニンb120
0mgとL−アラビノース50mgを生理食塩水0.1
mlに溶解したものを生理食塩水で1000分の1に希
釈した水溶液を1日1回2週間塗布した。2週間後に縫
合針を外し、断面1cmとなるように皮膚切片を作製し
た。この切片の切断張力を東洋測器株式会社製テンシロ
ンUTM−4を用いて測定した。(Wound healing effect) A group of 5 Wistar rats aged 6 weeks was used as a group and subjected to a test after hair cutting. After anesthetizing the rat with Nemptal, an incision of the back skin was made about 2 cm along the midline. Immediately, the incision was sutured with Mitsuhel, and 200 mg of saikosaponin b 1 was added to physiological saline 0.1.
those that have been dissolved ml, and or saikosaponin b 1 20
0 mg and L-arabinose 50 mg are added to physiological saline solution 0.1.
An aqueous solution prepared by diluting a solution dissolved in ml with physiological saline to 1/1000 was applied once a day for 2 weeks. Two weeks later, the suture needle was removed to prepare a skin section having a cross section of 1 cm. The cutting tension of this section was measured by using Tensilon UTM-4 manufactured by Toyo Sokki Co., Ltd.
【0024】サイコサポニンb1だけの場合の平均張力
は470g/cmであったのに対し、糖を添加したもの
の平均張力は510g/cmとなり、糖を配合すること
によりサイコサポニンb1の創傷治癒効果が向上するこ
とがわかった。また、サイコサポニンb2に関しては、
平均張力505g/cmが得られた。The average tension of the saikosaponin b 1 alone was 470 g / cm, whereas the average tension of the sugar-added one was 510 g / cm, and the wound healing of the saikosaponin b 1 was achieved by adding the sugar. It turned out that the effect improves. Also, regarding saikosaponin b 2 ,
An average tension of 505 g / cm was obtained.
【0025】(刺激性抑制効果)人の血液から赤血球を
採取し、サイコサポニンb1あるいはサイコサポニンb1
とL−アラビノース500ppmをそれぞれ加えて1時
間放置し、溶血量を測定した。サイコサポニンb1濃度
と溶血率の関係について得られた結果を図2に示す。[0025] The red blood cells from (stimulatory inhibitory effect) human blood was collected, Psycho saponin b 1 or saikosaponins b 1
And L-arabinose (500 ppm) were added and the mixture was allowed to stand for 1 hour to measure the amount of hemolysis. The results obtained for the relationship between the saikosaponin b 1 concentration and the hemolysis rate are shown in FIG.
【0026】図から明らかなように、糖L−アラビノー
スを添加することによりサイコサポニンb1の溶血作用
は高濃度まで抑制されることがわかった。As is clear from the figure, it was found that the hemolytic action of saikosaponin b 1 was suppressed to a high concentration by adding the sugar L-arabinose.
【0027】(実施例1及び比較例)表1に示した組成
の水相及びアルコール相をそれぞれ調製し、これらを混
合可溶化した後、ろ過して化粧水を作製した。(Example 1 and Comparative Example) A water phase and an alcohol phase having the compositions shown in Table 1 were prepared, mixed and solubilized, and then filtered to prepare a lotion.
【0028】[0028]
【表1】
試料1〜5は本発明の実施例、試料6 は比較例であ
る。このうち、試料1は請求項2及び3を満たす実施
例、試料2及び3は請求項3を満たす実施例、試料4及
び5は請求項2を満たす実施例である。[Table 1] Samples 1 to 5 are examples of the present invention, and sample 6 is a comparative example. Among these, sample 1 is an example satisfying claims 2 and 3, samples 2 and 3 are examples satisfying claim 3, and samples 4 and 5 are examples satisfying claim 2.
【0029】肌荒れ改善効果
試料1〜6の化粧水を用い、人体パネルで肌荒れ改善効
果試験を行った。試験方法は以下の通りである。Skin Roughness Improvement Effect Using the lotions of Samples 1 to 6, a skin roughness improvement effect test was conducted on a human body panel. The test method is as follows.
【0030】女性健常人の顔面表面形態をミリスン樹脂
によるレプリカ法を用いて肌のレプリカを取り、顕微鏡
で観察する。皮紋の状態及び角層の剥離状態から表2の
基準に基づいて肌あれ状態1あるいは2と評価されたパ
ネル25名の顔面左右半々に実施例の試料1〜5と比較
例の試料6の化粧水を1日1回2週間塗布した。The facial surface morphology of a healthy female is taken by replicating the skin using a replica method using myricin resin and observed with a microscope. Based on the condition of the skin print and the peeling state of the stratum corneum, based on the criteria of Table 2, the skin condition 1 or 2 was evaluated on the left and right sides of the face of each of the 25 panel members. The lotion was applied once a day for 2 weeks.
【0031】2週間後、再び上記のレプリカ法で肌の状
態を観察し、表2の基準に従い肌の状態を評価した。そ
の結果を表3にまとめた。After 2 weeks, the skin condition was observed again by the above replica method, and the skin condition was evaluated according to the criteria shown in Table 2. The results are summarized in Table 3.
【0032】[0032]
【表2】 [Table 2]
【0033】[0033]
【表3】
べたつき及び刺激性
試料1〜6の化粧水の各々について、25名のテスター
が実際に塗布し、それぞれの使用感(べたつき性、刺激
性)について官能評価した。各々の試料について、べた
つき、刺激を感じた人数を表4に示した。[Table 3] Stickiness and Irritation Twenty-five testers actually applied each of the lotions of Samples 1 to 6 and sensory-evaluated the feeling of use (stickiness, irritation) of each. Table 4 shows the number of people who felt stickiness and irritation for each sample.
【0034】[0034]
【表4】
表3及び4が示すように、比較例の試料6に比べ本実
施例の化粧水はいずれも肌あれ改善効果が向上し、特
に、請求項2及び3を満たす試料1は、極めて良好な肌
荒れ改善効果と高い使用感を示した。[Table 4] As shown in Tables 3 and 4, the lotion of the present example has an improved effect of improving skin roughness as compared with the sample 6 of the comparative example. Particularly, the sample 1 satisfying claims 2 and 3 has extremely good skin roughness. The improvement effect and high usability were exhibited.
【0035】また、サイコサポニンb1含有量が0.0
001重量%より少ない試料2では刺激性はないもの
の、肌荒れ改善効果が試料1に比べ劣っていた。サイコ
サポニンb1含有量が20%を越える試料3は、良好な
肌荒れ改善効果を示したが、べたつき感が現れることが
分かった。L−アラビノース含有量が0.01%より少
ない試料4は、肌荒れ改善効果が試料1及び3に比べ劣
り、また、L−アラビノース含有量が20%を越える試
料5は、試料1及び3と同様に良好な肌荒れ改善効果を
示すが、べたつき感が現れることが分かった。Further, the saikosaponin b 1 content is 0.0
Although the sample 2 with less than 001% by weight had no irritation, the rough skin improving effect was inferior to the sample 1. It was found that Sample 3 having a saikosaponin b 1 content of more than 20% showed a good effect of improving rough skin, but showed a sticky feeling. Sample 4, which has an L-arabinose content of less than 0.01%, is inferior in skin roughening improving effect to Samples 1 and 3, and Sample 5, which has an L-arabinose content of more than 20%, is similar to Samples 1 and 3. It was found that, although it shows a good effect of improving rough skin, a sticky feeling appears.
【0036】(実施例2〜6)以下の各実施例に示した
組成、製法に基づき作製した皮膚外用剤は従来例に比
べ、いずれも肌荒れ改善効果あるいは創傷治癒効果が向
上し、また刺激性も抑制され、糖がサイコサポニンb1
及びb2の上記効果を相乗的に向上することを示した。(Examples 2 to 6) The external preparations for skin prepared based on the compositions and manufacturing methods shown in each of the following Examples have improved rough skin improving effect or wound healing effect and are more irritating than conventional examples. Is also suppressed, and sugar is saikosaponin b 1
It was shown that the above effects of b and b 2 are synergistically improved.
【0037】(実施例2)
クリーム
重量%
(油相)
サイコサポニンb2 1.0
セトステアリルアルコール 3.5
スクワラン 38.0
ミツロウ 3.0
還元ラノリン 5.0
ステアリン酸エチル 4.0
エチルパラベン 0.3
香料 0.03
(水相)
D−ガラクトサミン 8.0
1,3−ブチレングリコール 2.0
グリセリン 2.0
イオン交換水 33.17
(製法)油相を加熱融解して75℃に保ち、これを7
5℃に加温した水相に攪拌しながら加えた。次にホモミ
キサーで均一に乳化した後、攪拌しながら急冷してクリ
ームを得た。(Example 2) Cream wt% (oil phase) Psychosaponin b 2 1.0 Cetostearyl alcohol 3.5 Squalane 38.0 Beeswax 3.0 Reduced lanolin 5.0 Ethyl stearate 4.0 Ethylparaben 0 .3 Fragrance 0.03 (aqueous phase) D-galactosamine 8.0 1,3-butylene glycol 2.0 glycerin 2.0 ion-exchanged water 33.17 (manufacturing method) The oil phase was melted by heating and kept at 75 ° C. This is 7
It was added with stirring to the aqueous phase heated to 5 ° C. Next, the mixture was uniformly emulsified with a homomixer and then rapidly cooled with stirring to obtain a cream.
【0038】(実施例3)
乳液
重量%
(アルコール相)
サイコサポニンb2 0.001
香料 0.03
エタノール 3.0
(油相)
ステアリン酸 1.5
セチルアルコール 0.5
ミツロウ 2.0
ポリオキシエチレン(10)オレイル 2.0
アルコール
エチルパラベン 0.3
(水相)
D−マンヌロン酸 5.0
プロピレングリコール 3.0
イオン交換水 62.669
クインスシード抽出液(5%水溶液) 20.0
(製法)70℃の水相に70℃で加熱溶融した油相を加
え、予備乳化を行い、更にホモミキサーで均一乳化し
た。これを攪拌しながら,アルコール相とクインスシー
ド抽出液を加え、30℃に冷却して乳液を得た。(Example 3) Emulsion weight% (alcohol phase) Psychosaponin b 2 0.001 Fragrance 0.03 Ethanol 3.0 (oil phase) Stearic acid 1.5 Cetyl alcohol 0.5 Beeswax 2.0 Polyoxy Ethylene (10) oleyl 2.0 Alcohol ethylparaben 0.3 (aqueous phase) D-mannuronic acid 5.0 Propylene glycol 3.0 Ion-exchanged water 62.669 Quinceseed extract (5% aqueous solution) 20.0 (production method) ) The oil phase heated and melted at 70 ° C. was added to the 70 ° C. aqueous phase, preliminarily emulsified, and further homogenized by a homomixer. While stirring this, an alcohol phase and a quince seed extract were added, and the mixture was cooled to 30 ° C. to obtain an emulsion.
【0039】(実施例4)
パック
重量%
サイコサポニンb1 0.1
ウンベリフェロース 5.0
ポリビニルアルコール 10.0
ポリエチレングリコール 3.0
プロピレングリコール 7.0
エタノール 10.0
メチルパラベン 0.05
香料 0.05
イオン交換水 64.8
(製法)イオン交換水にポリエチレングリコール、プ
ロピレングリコール、メチルパラベンを加え、攪拌溶解
した。次に、ポリビニルアルコールを加え加熱攪拌し、
サイコサポニンb1、ウンベリフェロース、香料を溶解
したエタノールを加え、攪拌溶解してパックを得た。Example 4 Pack Weight% Psychosaponin b 1 0.1 Umbelliferose 5.0 Polyvinyl alcohol 10.0 Polyethylene glycol 3.0 Propylene glycol 7.0 Ethanol 10.0 Methylparaben 0.05 Perfume 0.1. 05 Ion-exchanged water 64.8 (Production method) Polyethylene glycol, propylene glycol, and methylparaben were added to ion-exchanged water and dissolved with stirring. Next, add polyvinyl alcohol, heat and stir,
Psychosaponin b 1 , umbelliferose, and ethanol in which a fragrance was dissolved were added and dissolved by stirring to obtain a pack.
【0040】(実施例5)
頭皮用化粧料
重量%
(A相)
サイコサポニンb1 0.5
蔗糖 6.0
1,3−ブチレングリコール 6.5
ポリエチレングリコール1500 5.0
エタノール 5.5
水酸化カリウム 0.05
イオン交換水 40.95
(B相)
2−ヘキシルデシルパルミテート 10.0
スクワラン 5.0
ブチルパラベン 0.3
ビタミンEアセテート 0.15
香料 0.05
(C相)
イオン交換水 19.9
カルボキシビニルポリマー 0.2
(製法)B相を75℃で溶解したものを、75℃に加
熱したA相に攪拌しながら添加し、更に室温で攪拌溶解
したC相をし、攪拌しながら冷却して頭皮用化粧料を得
た。Example 5 Cosmetic for scalp wt% (Phase A) Psychosaponin b 1 0.5 Sucrose 6.0 1,3-Butylene glycol 6.5 Polyethylene glycol 1500 5.0 Ethanol 5.5 Hydroxylation Potassium 0.05 Ion-exchanged water 40.95 (Phase B) 2-Hexyldecyl palmitate 10.0 Squalane 5.0 Butylparaben 0.3 Vitamin E acetate 0.15 Perfume 0.05 (Phase C) Ion-exchanged water 19 .9 Carboxyvinyl Polymer 0.2 (Production Method) Phase B dissolved at 75 ° C was added to Phase A heated to 75 ° C with stirring, and then dissolved at room temperature with stirring to prepare Phase C and stirred. After cooling, a scalp cosmetic was obtained.
【0041】(実施例6)
軟膏
重量%
サイコサポニンb2 5.0
ヒアルロン酸 3.0
ワセリン 40.0
ステアリルアルコール 15.0
モクロウ 20.0
ポリオキシエチレン(10)オレイル 0.5
アルコール
イオン交換水 16.5
(製法)70℃のイオン交換水に70℃で混合溶解し
た他の成分を加え、ホモミキサーで均一乳化し、乳化後
冷却して軟膏を得た。(Example 6) Ointment wt% Saikosaponin b 2 5.0 Hyaluronic acid 3.0 Vaseline 40.0 Stearyl alcohol 15.0 Mokurou 20.0 Polyoxyethylene (10) oleyl 0.5 Alcohol ion-exchanged water 16.5 (Production method) Other components mixed and dissolved in 70 ° C. ion-exchanged water at 70 ° C. were added, the mixture was uniformly emulsified with a homomixer, and after emulsification, cooled to obtain an ointment.
【0042】[0042]
【発明の効果】本発明により、すなわちサイコサポニン
b1あるいはサイコサポニンb2に糖を配合することによ
り、サイコサポニンの細胞増殖作用が向上し、更に刺激
性も抑制される。その結果、肌荒れ防止及び改善効果、
皮膚老化防止効果または創傷治癒効果が高く及び使用感
の良好な皮膚外用剤を提供することが可能となる。INDUSTRIAL APPLICABILITY According to the present invention, that is, by adding a sugar to saikosaponin b 1 or saikosaponin b 2 , the cell-proliferating action of saikosaponin is improved and its stimulative property is suppressed. As a result, rough skin prevention and improvement effect,
It is possible to provide a skin external preparation having a high skin aging prevention effect or a wound healing effect and a good feeling in use.
【図1】サイコサポニンb1の細胞増殖効果が糖により
向上する事を示すグラフである。FIG. 1 is a graph showing that the cell growth effect of saikosaponin b 1 is improved by sugar.
【図2】赤血球の溶血が糖の添加により抑制される事を
示すグラフである。FIG. 2 is a graph showing that hemolysis of red blood cells is suppressed by the addition of sugar.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 FI 技術表示箇所 A61K 31/70 ADS 8314−4C 47/26 J 7329−4C 47/36 J 7329−4C ─────────────────────────────────────────────────── ─── Continuation of front page (51) Int.Cl. 5 Identification code Office reference number FI Technical indication location A61K 31/70 ADS 8314-4C 47/26 J 7329-4C 47/36 J 7329-4C
Claims (3)
b2の少なくとも1種と糖とを含有することを特徴とす
る皮膚外用剤。1. An external preparation for skin, comprising at least one of saikosaponin b 1 and saikosaponin b 2 and a sugar.
サポニンb2の少なくとも1種を0.0001〜20重
量%含むことを特徴とする請求項1記載の皮膚外用剤。 2. The external preparation for skin according to claim 1, comprising 0.0001 to 20% by weight of at least one of the saikosaponin b 1 and the saikosaponin b 2 .
を特徴とする請求項1または2項記載の皮膚外用剤。3. The external preparation for skin according to claim 1, which contains 0.01 to 20% by weight of the sugar.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP03195983A JP3135293B2 (en) | 1991-07-10 | 1991-07-10 | External preparation for skin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP03195983A JP3135293B2 (en) | 1991-07-10 | 1991-07-10 | External preparation for skin |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0517332A true JPH0517332A (en) | 1993-01-26 |
JP3135293B2 JP3135293B2 (en) | 2001-02-13 |
Family
ID=16350263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP03195983A Expired - Lifetime JP3135293B2 (en) | 1991-07-10 | 1991-07-10 | External preparation for skin |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3135293B2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995005155A1 (en) * | 1993-08-17 | 1995-02-23 | Roc S.A. | Use of oligosaccharides for the prevention and treatment of tissue ageing |
WO2000045802A3 (en) * | 1999-02-08 | 2001-03-01 | Idexx Lab Inc | Use of (alpha)-d-glucans for promoting cutaneous wound and ulcer healing |
JP2002539229A (en) * | 1999-03-18 | 2002-11-19 | ユニリーバー・ナームローゼ・ベンノートシヤープ | Skin cosmetic composition |
KR20130083793A (en) * | 2012-01-13 | 2013-07-23 | 주식회사 엘지생활건강 | Composition for improving skin wrinkle and enhancing elasticity |
-
1991
- 1991-07-10 JP JP03195983A patent/JP3135293B2/en not_active Expired - Lifetime
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995005155A1 (en) * | 1993-08-17 | 1995-02-23 | Roc S.A. | Use of oligosaccharides for the prevention and treatment of tissue ageing |
FR2709061A1 (en) * | 1993-08-17 | 1995-02-24 | Robert Ladislas | Use of oligosaccharides in the prevention and treatment of tissue aging. |
AU699585B2 (en) * | 1993-08-17 | 1998-12-10 | Roc S.A. | Use of oligosaccharides in the prevention and treatment of the aging of tissues |
WO2000045802A3 (en) * | 1999-02-08 | 2001-03-01 | Idexx Lab Inc | Use of (alpha)-d-glucans for promoting cutaneous wound and ulcer healing |
JP2002539229A (en) * | 1999-03-18 | 2002-11-19 | ユニリーバー・ナームローゼ・ベンノートシヤープ | Skin cosmetic composition |
KR20130083793A (en) * | 2012-01-13 | 2013-07-23 | 주식회사 엘지생활건강 | Composition for improving skin wrinkle and enhancing elasticity |
Also Published As
Publication number | Publication date |
---|---|
JP3135293B2 (en) | 2001-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1761450B (en) | Skin external preparation characterized by containing saccharide derivative of alpha, alpha-trehalose | |
US4822601A (en) | Cosmetic base composition with therapeutic properties | |
JP3687277B2 (en) | Whitening cosmetics | |
JPH0832621B2 (en) | Topical skin | |
JP2993915B2 (en) | Active agent for promoting epithelial exfoliation of skin comprising polyholoside, composition containing polyholoside, and use thereof | |
US4946832A (en) | Cosmetic base composition with therapeutic properties | |
EP0610511B2 (en) | Composition for dermatologic preparation | |
JP3251635B2 (en) | External preparation for skin | |
JP3135293B2 (en) | External preparation for skin | |
JP3443130B2 (en) | External preparation for skin | |
JPH09502159A (en) | Stable cosmetic composition | |
JPH069422A (en) | Promoter for biosynthesis of hyaluronic acid | |
JPH09291013A (en) | Skin cosmetic material | |
JP2002516836A (en) | Use of sophorolipids containing diacetylated lactones as stimulants of skin fibroblast metabolism | |
JP2000007550A (en) | Skin lotion | |
JP2000109419A (en) | Composition for moisturizing and composition for external use for skin containing the same | |
JP2023514303A (en) | Topically applicable lysate of dedifferentiated cells of the plant Helichrysum stoechas for moisturizing skin | |
JP3004707B2 (en) | External preparation for skin | |
JP2906198B2 (en) | External preparation for skin | |
JP2829157B2 (en) | External preparation for skin | |
JP3135295B2 (en) | External preparation for skin | |
JP3135294B2 (en) | External preparation for skin | |
JPH041115A (en) | Dermal drug for external use | |
JP3135296B2 (en) | External preparation for skin | |
JPH09241148A (en) | Skin external agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20001114 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071201 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081201 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081201 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091201 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101201 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101201 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111201 Year of fee payment: 11 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111201 Year of fee payment: 11 |